FDA will consider easing restrictions on peptides as RFK Jr. calls himself a “big fan”

The FDA plans to hold a meeting this summer to discuss easing restrictions on several peptide injections, which are unapproved therapies popular among wellness influencers and celebrities. Health Secretary Robert F. Kennedy Jr. has advocated for loosening these regulations, despite limited research on their safety and effectiveness. The FDA will consult a panel of outside advisers in July to determine if seven peptides, including BPC-157, should be safely produced by pharmacies. Currently, these peptides are on a restrictive list for unapproved, high-risk drugs. Critics, like Dr. Peter Lurie, warn that allowing peptides without clinical testing could undermine the FDA’s drug approval system. Under President Biden, the FDA had previously restricted peptides due to safety concerns. However, many of those involved in those decisions have since left the agency, and Kennedy may fill vacancies on the FDA’s pharmacy panel before the meeting. Kennedy has publicly supported peptides, claiming personal benefits from their use. QUESTION: How might the potential easing of restrictions on peptide injections impact public health and safety?